Blog > Pulmonary Arterial Hypertension Treatment Market Trends 2018 Rising Opportunities, Size, Share, Segments and Revenue Forecast 2028

Umesh
Comment (0)
Mar 07, 2019 07:23 PM

 

Owing to non-responsive nature of several advance pharmacotherapies and high diagnosis and treatment costs, researchers and medical practitioners in the global pulmonary arterial hypertension treatment market are continually working on favorable and effective alternative treatment models and increase survival rate among the patients with pulmonary arterial hypertension.

Future Market Insights, in its recently published outlook on the global market for pulmonary arterial hypertension treatment market, projects the US$ 5 billion market to barely exceed US$ 6.5 billion in terms of revenue, through the next decade. The market has been estimated at a sluggish CAGR of 2.5% over 2018-2028. However, innovations and combination therapeutics are likely to forestall further decline of the pulmonary arterial hypertension treatment market in near future.

Cancer Protein Molecules Tested for Potential Therapeutic Use- to Prevent Pulmonary Arteries ‘Scarring’

Scarring or Fibrosis, in pulmonary arterial hypertension, is an important cause of damage to pulmonary arteries, which in turn, strains the heart functions- eventually leading to breathlessness. Recently, researchers from Brigham and Women's Hospital conducted a study using network medicine- a method of establishing correlation between proteins, pathways and more- and identified the cancer protein NEDD9 and its molecular mechanisms as a potential treatment for PAH patients. The study has identified that a specific amino acid residue in the cancer protein is expected to play a crucial role in controlling and regulating the severe consequences of scarring.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1218 

BH4- Factor Controlling Production of Nitric Oxide- Shows Promising Result on Rat Model; Results Show Lower Lung Hypertension

Researchers at Imperial College London and Bar-Ilan University, Israel explored the properties of naturally occurring tetrahydrobiopterin (BH4) and its subsequent role in effective treatment for lung hypertension and right heart failure. BH4 controls the production of endothelial nitric oxide synthase (eNOS) in the human body. eNOS produces nitric oxide which is important for healthy endothelial cells- forming the inside lining of blood vessels. Nitric oxide is responsible for dilating blood vessels, working to lower lung blood pressure.

The study- conducted on a rats first in injected with chemical triggering pulmonary hypertension and then an injection of BH4, showed signs of decreased lung pressure, stronger heart contractions and, enlarged heart.  The rats were then given BH4 in food before the chemical that previously induced pulmonary hypertension. As a result of which, no thick layers of smooth muscles were developed- often leading to lung hypertension.

After the phase 1 of clinical trials, the patients- administered BH4 orally, showed improved exercise capacity- an indicator of low pressure in lungs. It is anticipated that BH4, when given controlled measure could prove to a valuable treatment for pulmonary arterial hypertension patients who otherwise are not responsive to regular medication.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-1218

With Treatment Options, ‘Accurate Risk Measuring’ Tools is the Need of the Hour

Although measurable efforts are being made in the global pulmonary arterial hypertension treatment market, the survival rate among PAH patients continues to remain low.  According to studies, the average life expectancy of PAH patient is approximately 3 years from symptom onset- being at a risk of disease progression and frequent hospitalizations. Several studies indicate that early diagnosed and ‘low-risk’ patients stand a chance of improved survival if the risk is calculated accurately. Experts have expressed the need to develop appropriate and accurate risk prediction tools improve treatment outcomes in PAH patients.

Post Your Comment

Be the first one to post comment

Featured Businesses

Featured businesses list is created by admin on as per the request of business owners when adding their business and must add all information like logo, social link and description

DayRise Solar Enerdy Pvt Ltd

DayRise Solar Enerdy Pvt...

DayRise Solar provide one stop solution for all your requirements in the field of Solar Energy, Security Surveillance and WiFi Networking. We deal...

Dink Cart

Dink Cart

Dinkcart offer custom t shirt, mugs, caps, pen printing services in Delhi ncr. customized & personalized T shirt, bulk tshirt printing in Delhi,...

Norton Setup 1-844-777-7886

Norton Setup 1-844-777-7886

Norton Setup with your product key online. Download & Install Norton Product, Visit activation website norton.com/setup to register your code.

Express Employment Professionals of Tigard, OR

Express Employment Profe...

Locally owned and operated, Express Employment Professionals in Tigard, OR is a Full-Service Staffing Agency that continually exceed expectations...

© 2019 OneFDH. All Rights Reserved.
Follow us on